Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 0 5 35 28 versus NORTREL 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 0 5 35 28 versus NORTREL 1 35 21.
NORTREL 0.5/35-28 vs NORTREL 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone and ethinyl estradiol are a combination hormonal contraceptive. Norethindrone suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and enhances the contraceptive effect by inhibiting gonadotropin secretion.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
1 tablet orally once daily for 28 days (21 active tablets containing 0.5 mg norethindrone and 35 mcg ethinyl estradiol, followed by 7 placebo tablets).
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Norethindrone: 7.2-9.2 hours; Ethinyl estradiol: 13-27 hours. Clinical context: Steady state reached in 5-7 days; half-life supports once-daily dosing.
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites; <5% unchanged.
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive